Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs. 2018 Apr 02.

View in: PubMed

authors with profiles

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement